Evidence map›Paper›PMID 41642467›Full record

ArticleCEN case reports2026

A case of membranous proliferative glomerulonephritis-type IgA nephropathy modified by nintedanib.

Yasushi Kunisho, Tadashi Sofue, Hirona Nagano, Masato Higashitani, Takafumi Shiga, Aiko Shiraishi, Yuhei Aoki, Keisuke Onishi, Emi Ibuki, Tetsuo Minamino

Erratum issuedAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Yasushi KunishoDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. kunisho.yasushi@kagawa-u.ac.jp.ORCID 0009-0004-1915-1340
Tadashi SofueDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Hirona NaganoDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Masato HigashitaniDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Takafumi ShigaDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Aiko ShiraishiDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Yuhei AokiDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Keisuke OnishiDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
Emi IbukiMolecular Oncologic Pathology, Department of Pathology and Host Defense, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Tetsuo MinaminoDepartment of CardioRenal and CerebroVascular Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 73-year-old woman had been treated with nintedanib for 40 months for idiopathic pulmonary fibrosis. She presented to our hospital with lower extremity edema since a month and nephrotic syndrome (serum albumin 2.0 mg/dL, urine protein 7.97 g/g Cr). We performed a renal biopsy and diagnosed membranoproliferative glomerulonephritis (MPGN)-type IgA nephropathy (IgAN). We hypothesized that nintedanib-induced microangiopathy modified subclinical IgAN and caused the appearance of MPGN-type IgAN and nephrotic syndrome. After the discontinuation of nintedanib, the urinary protein level improved to 0.5 g/g Cr, and hematuria disappeared.

Indexed as

Glomerulonephritis, IGAGlomerulonephritis, MembranoproliferativeIndolesAgedBiopsyFemaleHematuriaHumansIdiopathic Pulmonary FibrosisKidneyNephrotic SyndromeProteinuriaIndolesnintedanibIgA nephropathy (IgAN)Membranous proliferative glomerulonephritis (MPGN)NintedanibThrombotic microangiopathy (TMA)

Identifiers

PMID41642467
PMCPMC12876549

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.